ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Avanir Pharmaceuticals, Inc. Class A" (AVNR) Report Updated: Jul 21, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Avanir Pharmaceuticals, Inc. Class A" (AVNR)

Rating: Hold Volatility: Moderate
Total Grade: C Industry: Pharmaceuticals
Competitors: PTIE, MRK, LCI, AKRX
service keys

"Avanir Pharmaceuticals, Inc. Class A"© quotemedia

Company Profile

Avanir Pharmaceuticals, Inc., together with its subsidiaries, engages in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States. The company primarily offers NUEDEXTA, a unique proprietary combination of dextromethorphan and low-dose quinidine for the treatment of pseudobulbar affect. Its product line also comprises AVP-923 in Phase II clinical trial for the treatment of central neuropathic pain in patients with multiple sclerosis; and in Phase III trial for the treatment of patients with diabetic peripheral neuropathic pain. In addition, the company provides Docosanol 10% cream, an over-the-counter product for cold sores treatment. Avanir Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Aliso Viejo, California.

Recent News: "Avanir Pharmaceuticals, Inc. Class A"